Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis
- 1 September 1999
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 13 (13), 1687-1695
- https://doi.org/10.1097/00002030-199909100-00012
Abstract
To examine the effects of antiretroviral therapy (ART) and opportunistic illness chemoprophylaxis on the survival of persons with AIDS and survival time based on year of AIDS diagnosis. Longitudinal medical record review. Ninety-three hospitals and clinics in nine cities in the USA. We observed 19,565 persons with AIDS from 1990 through January 1998. Prescribed use of antiretroviral monotherapy, dual- and triple-combination therapies, primary prophylaxis against Pneumocystis carinii pneumonia and Mycobacterium avium complex, and pneumococcal vaccine. Time from AIDS diagnosis to death in the presence and absence of ART. Survival curves were compared of AIDS cases diagnosed during 1990-1992 and 1993-1995. Triple ART had the greatest effect on the risk of death [relative risk (RR), 0.15; 95% confidence limit (CL), 0.12, 0.17], followed by dual ART (RR, 0.24; 95% CL, 0.22, 0.26), and monotherapy (RR, 0.38; 95% CL, 0.36, 0.40). Risk of death was decreased among persons receiving Pneumocystis carinii pneumonia prophylaxis (RR, 0.79; 95% CL, 0.70, 0.89) and Mycobacterium avium complex prophylaxis (RR, 0.76; 95% CL, 0.68, 0.86). Median survival increased from 31 months [95% confidence interval (CI), 30-32 months] for AIDS cases diagnosed during 1990-1992 to 35 months (95% CI, 35-38 months) for cases diagnosed during 1993-1995. The risk of death was decreased for persons receiving triple ART compared with persons receiving dual therapy and persons receiving monotherapy. Increased use of ART and improved ART regimens probably contributed to prolonged survival of persons whose diagnosis was made during 1993-1995 compared with persons whose diagnosis was made during 1990-1992.Keywords
This publication has 35 references indexed in Scilit:
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- A Randomized Trial of Clarithromycin as Prophylaxis against DisseminatedMycobacterium aviumComplex Infection in Patients with Advanced Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1996
- Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USAPublished by American Medical Association (AMA) ,1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus DiseaseNew England Journal of Medicine, 1995
- Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complexAIDS, 1995
- Predictors Of Survival In Patients With Aids And Disseminated Mycobacterium Avium Complex DiseaseThe Journal of Infectious Diseases, 1994
- Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993Published by American Medical Association (AMA) ,1994
- The Effects on Survival of Early Treatment of Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992